Literature DB >> 29774570

High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.

Xiaodong Ge1,2, Elena Arriazu2, Fernando Magdaleno1, Daniel J Antoine3, Rouchelle Dela Cruz4, Neil Theise4,5, Natalia Nieto1,2,6.   

Abstract

High-mobility group box-1 (HMGB1) is a damage-associated molecular pattern (DAMP) increased in response to liver injury. Because HMGB1 is a ligand for the receptor for advanced glycation endproducts (RAGE), we hypothesized that induction of HMGB1 could participate in the pathogenesis of liver fibrosis though RAGE cell-specific signaling mechanisms. Liver HMGB1 protein expression correlated with fibrosis stage in patients with chronic hepatitis C virus (HCV) infection, primary biliary cirrhosis (PBC), or alcoholic steatohepatitis (ASH). Hepatic HMGB1 protein expression and secretion increased in five mouse models of liver fibrosis attributed to drug-induced liver injury (DILI), cholestasis, ASH, or nonalcoholic steatohepatitis (NASH). HMGB1 was up-regulated and secreted mostly by hepatocytes and Kupffer cells (KCs) following CCl4 treatment. Neutralization of HMGB1 protected, whereas injection of recombinant HMGB1 promoted liver fibrosis. Hmgb1 ablation in hepatocytes (Hmgb1ΔHep ) or in myeloid cells (Hmgb1ΔMye ) partially protected, whereas ablation in both (Hmgb1ΔHepΔMye ) prevented liver fibrosis in vivo. Coculture with hepatocytes or KCs from CCl4 -injected wild-type (WT) mice up-regulated Collagen type I production by hepatic stellate cells (HSCs); yet, coculture with hepatocytes from CCl4 -injected Hmgb1ΔHep or with KCs from CCl4 -injected Hmgb1ΔMye mice partially blunted this effect. Rage ablation in HSCs (RageΔHSC ) and RAGE neutralization prevented liver fibrosis. Last, we identified that HMGB1 stimulated HSC migration and signaled through RAGE to up-regulate Collagen type I expression by activating the phosphorylated mitogen-activated protein kinase kinase (pMEK)1/2, phosphorylated extracellular signal-regulated kinase (pERK)1/2 and pcJun signaling pathway.
Conclusion: Hepatocyte and KC-derived HMGB1 participates in the pathogenesis of liver fibrosis by signaling through RAGE in HSCs to activate the pMEK1/2, pERK1/2 and pcJun pathway and increase Collagen type I deposition.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29774570      PMCID: PMC6240507          DOI: 10.1002/hep.30093

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

2.  Role of ALK5/Smad2/3 and MEK1/ERK Signaling in Transforming Growth Factor Beta 1-modulated Growth, Collagen Turnover, and Differentiation of Stem Cells from Apical Papilla of Human Tooth.

Authors:  Hsiao-Hua Chang; Mei-Chi Chang; I-Hua Wu; Guay-Fen Huang; Wei-Ling Huang; Yin-Lin Wang; Sheng-Yang Lee; Chien-Yang Yeh; Ming-Kuang Guo; Chiu-Po Chan; Hsiang-Chi Hsien; Jiiang-Huei Jeng
Journal:  J Endod       Date:  2015-05-19       Impact factor: 4.171

3.  Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.

Authors:  Sandro Jube; Zeyana S Rivera; Marco E Bianchi; Amy Powers; Ena Wang; Ian Pagano; Harvey I Pass; Giovanni Gaudino; Michele Carbone; Haining Yang
Journal:  Cancer Res       Date:  2012-05-02       Impact factor: 12.701

4.  Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice.

Authors:  Raul Lazaro; Raymond Wu; Sunyoung Lee; Nian-Ling Zhu; Chia-Lin Chen; Samuel W French; Jun Xu; Keigo Machida; Hidekazu Tsukamoto
Journal:  Hepatology       Date:  2014-11-25       Impact factor: 17.425

5.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 6.  Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach.

Authors:  Neil D Theise
Journal:  Mod Pathol       Date:  2007-02       Impact factor: 7.842

7.  CD24 and Siglec-10 selectively repress tissue damage-induced immune responses.

Authors:  Guo-Yun Chen; Jie Tang; Pan Zheng; Yang Liu
Journal:  Science       Date:  2009-03-05       Impact factor: 47.728

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 9.  High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.

Authors:  Marco E Bianchi; Angelo A Manfredi
Journal:  Immunol Rev       Date:  2007-12       Impact factor: 12.988

10.  Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD.

Authors:  Umberto Vespasiani-Gentilucci; Simone Carotti; Giuseppe Perrone; Chiara Mazzarelli; Giovanni Galati; Andrea Onetti-Muda; Antonio Picardi; Sergio Morini
Journal:  Liver Int       Date:  2014-04-05       Impact factor: 5.828

View more
  29 in total

1.  Activated cholangiocytes release macrophage-polarizing extracellular vesicles bearing the DAMP S100A11.

Authors:  Tomohiro Katsumi; Maria Eugenia Guicciardi; Adiba Azad; Steven F Bronk; Anuradha Krishnan; Gregory J Gores
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

Review 2.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

3.  The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver.

Authors:  Ingmar Mederacke; Aveline Filliol; Silvia Affo; Ajay Nair; Celine Hernandez; Qiuyan Sun; Florian Hamberger; Francesco Brundu; Yu Chen; Aashreya Ravichandra; Peter Huebener; Helena Anke; Hongxue Shi; Raquel A Martínez García de la Torre; James R Smith; Neil C Henderson; Florian W R Vondran; Carla V Rothlin; Heike Baehre; Ira Tabas; Pau Sancho-Bru; Robert F Schwabe
Journal:  Sci Transl Med       Date:  2022-04-06       Impact factor: 19.319

Review 4.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

Review 5.  Liver regeneration and inflammation: from fundamental science to clinical applications.

Authors:  Lara Campana; Hannah Esser; Meritxell Huch; Stuart Forbes
Journal:  Nat Rev Mol Cell Biol       Date:  2021-06-02       Impact factor: 94.444

6.  HMGB1-Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice.

Authors:  Xin-Lin Zhang; Ting-Yu Wang; Zheng Chen; Hong-Wei Wang; Yong Yin; Lian Wang; Yong Wang; Biao Xu; Wei Xu
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

Review 7.  Role of High-Mobility Group Box-1 in Liver Pathogenesis.

Authors:  Bilon Khambu; Shengmin Yan; Nazmul Huda; Xiao-Ming Yin
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

8.  Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathway.

Authors:  Xiaodong Shi; Lijia Yu; Yinglin Zhang; Zequan Liu; Huawei Zhang; Yansong Zhang; Ping Liu; Peishuang Du
Journal:  Int Immunopharmacol       Date:  2020-05-08       Impact factor: 4.932

Review 9.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07

Review 10.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.